GIS’ Biotech Startup Nalagenetics Raises US$12.6m In Series A Funding Round
Nalagenetics Team Singapore . Prof Liu Jian Jun, Co-Founder and Super Advisor (1st row, 1st from the left), Levana Sani, Co-Founder and CEO (1st row, 2nd from the left), Astrid Irwanto, Co-Founder and COO (1st row, 4th from the left), and Alexander Lezhava , Co-Founder and Super Advisor (2nd row, 1st from the right).
Nalagenetics, a spin off from A*STAR’s GIS, was recently featured in the Business Times on 25 March 2022 for raising US$12.6 million in a Series A funding round.
Founded in 2016, Nalagenetics is a biotechnology company focused on personalised screening and intervention. It aims to provide affordable and actionable end to end genetic testing that is relevant to local populations. The company has four product pillars: Clinical Decision Support for physicians, genetic tests, Knowledge Base and algorithms to generate clinically actionable reports, and Patient Engagement.
For more information, please visit http://www.nalagenetics.com.
A*STAR celebrates International Women's Day
From groundbreaking discoveries to cutting-edge research, our researchers are empowering the next generation of female science, technology, engineering and mathematics (STEM) leaders.
Get inspired by our #WomeninSTEM